NYSE : BMN
-$0.06 (-0.24%)
NYSE
John M. Perlowski
Asset Management
Financial Services
BMN
N/A
US
USD
212 810 5300
09262G108
0001832871
-$
-$
%
%
%
%
0/5
0 Analysts
%
About Blackrock 2037 Municipal Target Term Trust (NYSE:BMN) Stock
Launched by BlackRock, Inc., the BlackRock 2037 Municipal Target Term Trust operates as a closed-end mutual fund specializing in fixed-income investments. Its operations are overseen by BlackRock Advisors, LLC. The fund primarily allocates its capital to investment-grade municipal securities, requiring a minimum rating of BBB- from S&P and Fitch, or Baa3 from Moody's. This trust is officially domiciled in the United States. ...
2026-06-16 09:05:00
Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia New Phase 1 results also presented for investigational BMN 333 support potential weekly dosing in children with achondroplasia SAN RAFAEL, Calif., June 16, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the Endocrine Society Annual Meeting, in Chicago.
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
2026-05-18 09:05:00
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration, one of the study's co-primary endpoints; however, no improvement was observed in Radiographic Global Impression of Change (RGI-C) scores, the study's other co-primary endpoint and an important clinical measure of change in rickets severity Company is evaluating data to determine next steps SAN RAFAEL, Calif., May 18, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced results from the pivotal Phase 3 ENERGY 3 trial evaluating BMN 401 in children aged 1-12 with ENPP1 deficiency, a rare, serious and progressive genetic condition.
Bitcoin surged in April, but weak buyer demand makes the rally vulnerable
2026-05-01 11:57:34
Bitcoin gained 12.7% in April, registering back-to-back monthly gains and its best month since April 2025. The run was driven by leveraged trading activity in the derivatives market while demand for the spot bitcoin contracted, signaling weakness in the rally, according to CryptoQuant.
Frequently Asked Questions
What is the current Blackrock 2037 Municipal Target Term Trust (BMN) stock price?
Blackrock 2037 Municipal Target Term Trust(NYSE:BMN) stock price is $25.45 in the last trading session. During the trading session, BMN stock reached the peak price of $27.96 while $23.96 was the lowest point it dropped to. The percentage change in BMN stock occurred in the recent session was --0.24% while the dollar amount for the price change in BMN stock was -$0.06.
BMN's industry and sector of operation?
The NYSE listed BMN is part of Asset Management industry that operates in the broader Financial Services sector.
Who are the executives of BMN?
|
|
|
|
|
How many employees does BMN have?
Number of BMN employees currently stands at None. BMN operates from 55 East 52nd Street, New York City, NY 10055, US.
Link for BMN official website?
Official Website of BMN is: https://www.blackrock.com/us/individual/products/329661/blackrock-2037-municipal-target-term-trust-class
How do I contact BMN?
BMN could be contacted at phone #212 810 5300 and can also be accessed through its website. BMN operates from 55 East 52nd Street, New York City, NY 10055, US.
How many shares of BMN are traded daily?
The average number of BMN shares traded daily for last 3 months was 9.3K.
What is the market cap of BMN currently?
The market value of BMN currently stands at $156.46M with its latest stock price at $25.45